English | Deutsch

Third-party funding and current grant support

Research of our group mainly relies on third-party funding. Over the last decade in total 6 million Euros could be spent. The table and diagram below show the annually spent funds, divided into funding sources.

Funding / Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
DFG 76,862 184,502 121,370 141,476 178,781 196,919 154,190 79,481 79,321 129,750 210,276 232,971 159,076 86,656
BMBF 118,215 174,212 245,606 46,383 425,146 234,212 182,395 52,559 55 52,183
EU 58,641 134,536 27,203 8,454 252,122 380,152 345,217
US, NIH 51,280 3,057 7,374 851 15,859
Industry 197,260 337,798 175,812 244,143 189,998 164,740 162,885 370,532 131,077 131,324 169,434 129,200 100,933 63,574
Sum 392,337 696,512 542,788 490,643 503,315 440,142 320,132 450,013 635,544 503,740 562,105 674,226 641,067 563,489
German Research Foundation (DFG, blue)
German Minister of Science and Research (BMBF, yellow)
European Community (EU, gray)
National Institute of Health (US, green)
Industry fundings (Industry, red)

Recent and Current Funding ID

Funding agency Title Funding in Euro
DFG Structural studies of Shigella-specific Pathogenicity Factors as a Prerequisite for Rational Drug Design 189,750
DFG Understanding the Binding Characteristics of Aldose Reductase 113,250
DFG Structure-based Design, Synthesis and Crystallographic Characterisation of Aspartyl protease Inhibitors: Target proteins for HIV- and Malaria-infection 132,550
DFG - FO 806 Cross-correlation of Protein Binding Pockets to detect related Binding Epitopes, unexpected Cross-reactivity and Functional Relationships 216,000
DFG Interfering with Intracellular Protein-protein Interactions - Probing Protein Functions with Small Molecules, Perturbance of Enzyme Function by Blocking Dimer Interface Formation: Novel Route to Specific Antibiotics 289,100
CCDC Development of a Scoring Function 28,402
CCDC Studentship on Cambridge Structural Database – Knowledge-based Hot Spot Analysis 106,812
Bayer Schering From Targets to Novel Drugs 50,000
Sanofi Comparison of Binding Pocket using Cavbase to Analyse and Correlate Proteins across Protein Families and Design of Focused Libraries for de novo Design 111,000
Beiersdorf Design of Inhibitors for humane Tyrosinase by Molecular Modeling and Crystallography 126,000
BMBF Fragmentscreening "FragScreen" BioChance Plus, New methods for Experimental and Computational Fragment-based Drug Design 910,876
BMBF Zedira Development of Factor XIIIa - Inhibitors to Prevent Thrombosis 100,000
LOEWE Synmikro Data Mining Methoden zur graphbasierten Analyse von Proteinstrukturdaten, Protein-Ligand & Protein-Protein Interaktionen 132,300
LOEWE Synmikro Development of novel bioinformatics methods for the prediction of protein function and interactions. Experimental validation 168,000
ERC AG Chemogenomic profiling of drug-protein binding by shape, enthalpy/entropy and interaction kinetics 1,754,615
BMBF FKZ Aufbau einer "Beamline zum direkten Fragmentscreening" an Proteinkristallen zur Leitstrukturentwicklung 640,609
DFG 17beta-Hydroxysteroid Dehydrogenase Typ 14: Enzymstruktur-basierte Entwicklung von potenten und selektiven Inhibitoren mit Hilfe von Kristallisation und Enzymcharakterisierung 156,500
LOEWE SynChemBio Innovative Synthesechemie für die selektive Modulation biologischer Prozesse - Schwerpunkt S-07 140,000
DFG Durchführung einer Tagung FiMC 25,000
BMBF Zedira Entwicklung von Faktor XIIIa - Inhibitoren zur Thromboprophylaxe - Stufe 2 59,901
Total 5,450,665